Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

roche_good

Roche finds contradictory results in identical Phase III asthma trials

February 29, 2016 Manufacturing and Production, Research and Development Roche, lebrikizumab asthma

Roche has reported contradictory results from two identical Phase III studies of lebrikizumab in severe asthma, with one showing the …
News
ucb_logo

New epilepsy drug launches in UK

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …
News
roche_glass_building

FDA approves Roche’s Gazyva in follicular lymphoma

February 29, 2016 Research and Development, Sales and Marketing Levact, MabThera

Strong Phase III results have seen the US FDA approve Roche’s Gazyva (obinutuzumab) plus Levact (bendamustine) chemotherapy followed by Gazyva …
News
findacure

Drug repurposing can help tackle Rare Diseases, says charity

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing rare diseases

On Rare Disease Day 2016, UK charity Findacure says existing drugs may hold the key to new treatments and repurposing …
News
boehringer_good

Boehringer launches IPF initiatives

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …
News
afinitor

FDA approves new indication for Novartis’ Afinitor

February 29, 2016 Research and Development, Sales and Marketing Afinitor, Novartis

Novartis’ cancer drug Afinitor (everolimus) has been granted FDA approval in a new indication: for the treatment of adult patients …
News
eisai_logo

Eisai slams new Cancer Drugs Fund for delaying patient access

February 26, 2016 Research and Development, Sales and Marketing Cancer Drugs Fund, Eisai, Lenvima

Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …
News
gilead-sciences

Positive CHMP opinion for Gilead’s Descovy

February 26, 2016 Research and Development Gilead Sciences

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has adopted a positive opinion …
News
boehringer_good

Boehringer’s OFEV slows IPF disease progression by half in trials

February 26, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev

Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …
News

INTERVIEW: AstraZeneca on the Cancer Drugs Fund reforms

February 26, 2016 Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund

Greg Rossi, head of the Oncology Business Unit, AstraZeneca UK and Ireland, and the company’s market access team, spoke to …
Feature

Obama announces acceleration of Precision Medicines Initiative

February 26, 2016 Medical Communications, Research and Development Obama, Precision Medicine, cancer moonshot, genomics

A year after Barack Obama announced the $200 million Precision Medicines Initiative (PMI), the US President yesterday outlined the next …
News
msd

MHRA approves new indication for MSD’s Ezetrol

February 26, 2016 Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …
News
nhs_sign

NHS England approves Cancer Drugs Fund proposals

February 26, 2016 Medical Communications, Research and Development ABPI, Cancer Drugs Fund, NHS England

NHS England has approved proposed reforms of the Cancer Drugs Fund, following the end of the 12-week consultation period earlier …
News
ema_logo

EMA recommends AZ/Acerta drug for orphan status in three indications

February 25, 2016 Research and Development AstraZeneca, EMA, Orphan Drugs

The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended AstraZeneca and Acerta’s acalabrutinib (ACP-196) for designation …
News
medicines_patent_pool2

The Medicines Patent Pool – five years on

February 25, 2016 Research and Development, Sales and Marketing

Introduction The Medicines Patent Pool (MPP) was founded five years ago as a program to improve access to affordable and …
Feature
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026